

**Retina Update (04/23/22 @ 8 a.m. ET)**

**Saturday, April 23, 2022**

*Wills Eye Auditorium*

**[Conference Description:](https://willseye.cloud-cme.com/course/courseoverview?P=0&EID=321" when registering for the event.With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.More information to come." ")**

[Click Here to Sign Up for the Livestream](https://willseye.cloud-cme.com/course/courseoverview?P=0&EID=321" when registering for the event.With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.More information to come." ")

[Wills Eye Hospital is re-opening Saturday Updates to a limited number of guests to attend in-person.](https://willseye.cloud-cme.com/course/courseoverview?P=0&EID=321" when registering for the event.With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.More information to come." ")

[If you would like to attend in-person, please select the in-person option when registering for the event.](https://willseye.cloud-cme.com/course/courseoverview?P=0&EID=321" when registering for the event.With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.More information to come." ")

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://willseye.cloud-cme.com/course/courseoverview?P=0&EID=321" when registering for the event.With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.More information to come." ")

[More information to come.](https://willseye.cloud-cme.com/course/courseoverview?P=0&EID=321" when registering for the event.With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.More information to come." ")

**At the conclusion of the course, participants should be able to:**

1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.

2 Identify basic and clinical vision research that can be transformed into improved clinical care.

3 Assess the role of new technologies in the evaluation and treatment of eye diseases.

4 Describe factors that impact the effective delivery of the highest quality eye care for the public.

5 Identify clinical, scientific, and ethical issues confronting the profession.

6 Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Peggy Semen | Activity Administrator |  |
| David Brown, MD | Faculty | Advisor-Alexion Pharmaceuticals|Advisor-Allergan|Advisor-Apellis Pharmaceuticals|Advisor-Boehringer Ingelheim|Advisor-Clearside Biomedical|Advisor-Genentech|Advisor-Glaukos Corporation|Advisor-Heidelberg Engineering|Advisor-Kodiak Sciences|Royalties or Patent Beneficiary-MedOne Surgical, Inc.|Advisor-Novartis|Advisor-Regeneron|Advisor-REGENXBIO, Inc.|Advisor-Santen Pharmaceuticals|Advisor-Senju - 04/11/2022 |
| Allen Chiang, MD | Faculty | Grant or research support-Genentech|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Apellis Pharmaceuticals|Consulting Fee-Apellis Pharmaceuticals (Relationship has ended) - 01/07/2022 |
| Michael N. Cohen, MD | Faculty | Consultant / Independent Contractor-Allergan|Consultant / Independent Contractor-Keeler, Inc. - 05/04/2021 |
| Allen Ho, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Alcon|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Independent Contractor (included contracted research)-Kodiak Sciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Notal Vision|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Orbit Biomedical|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron|Membership on Advisory Committees or Review Panels, Board Membership, etc.-REGENXBIO, Inc. - 12/05/2021 |
| Jason Hsu, MD | Faculty | Advisor / Board Member-IVERIC Bio|Grant / Research Support-IVERIC Bio|Consultant / Independent Contractor-Gyroscope Therapeutics|Consultant / Independent Contractor-OccuRx|Grant / Research Support-Genentech|Grant / Research Support-Aldeyra Therapeutics - 08/13/2021 |
| Michael A. Klufas, MD | Faculty | Consulting Fee-Allergan|Speakers Bureau-Regeneron|Consulting Fee-Genentech|Consulting Fee-REGENXBIO, Inc. - 12/06/2021 |
| Ajay E. Kuriyan, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Recens medical - 11/06/2021 |
| Sonia Mehta, MD | Faculty | Nothing to disclose - 04/30/2021 |
| Rebecca A Procopio, MD | Faculty | Nothing to disclose - 03/16/2022 |
| Joseph Pulido, MD, MS, MBA, MPH | Faculty | Nothing to disclose - 01/15/2022 |
| Carl D. Regillo, MD | Faculty | Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Grant or research support-Regeneron - 11/10/2021 |
| Duo Xu, MD | Faculty | Consulting Fee-Gyroscope Therapeutics|Advisor-Apellis|Consulting Fee-Bausch + Lomb - 04/11/2022 |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Stocks or stock options, excluding diversified mutual funds-Merck - 01/15/2022 |

